Skip to content
Open access

Internal validation of a residual thyroid recurrence model after PTC

Jul 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 26 references
Medicine

TL;DR

An innovative clinical prediction model specifically designed to assess the risk of recurrence in residual thyroid tissue is developed and validated and serves as a valuable tool for clinicians, facilitating personalized decision-making and representing a significant advancement in the postoperative management of papillary thyroid carcinoma.

Abstract

Background At present, the risk factors contributing to the recurrence of papillary thyroid carcinoma (PTC) in residual thyroid tissue post-surgery are not yet fully understood. This study sought to identify multivariable predictors (MVPs) associated with such recurrence and to develop a dynamic, individualized nomogram. The objective is to establish a stratification framework to inform precision “risk-intervention” decision-making for patients at elevated risk of recurrence. Methods A cohort of 2,512 patients diagnosed with thyroid cancer and treated at the First Affiliated Hospital of Bengbu Medical University between January 2014 and December 2024 was analyzed. The cohort was stratified into a training set (n = 1,760) and a validation set (n = 752) using stratified random sampling with a 7:3 ratio. To address the class imbalance between recurrent and non-recurrent cases in the residual thyroid, the Random Over-Sampling Examples (ROSE) method was employed on the training set. Variable selection was conducted using univariate and multivariate logistic regression, LASSO regression, and standard stepwise regression based on the Akaike Information Criterion (AIC). A nomogram was subsequently developed by integrating the coefficients of the selected variables from the logistic regression model. The performance of the nomogram was assessed in both cohorts in terms of discrimination, calibration, and clinical utility. Results In a study of 2,512 thyroid cancer patients who received primary treatment, 146 experienced recurrence in the remaining thyroid tissue. Using univariate and multivariate logistic regression and LASSO regression for feature selection, four independent predictors were identified for the final predictive model: maximum tumor diameter, number of metastatic lymph nodes, lymph node positivity rate, and age. The nomogram showed strong discriminatory ability, with an AUC of 0.7518 in the training set and 0.8347 in the validation set. It also demonstrated excellent calibration and clinical utility across all groups. The best cut-off value for the nomogram score to identify patients with residual thyroid recurrence was 0.245, with scores above this linked to a significantly worse postoperative outcome. Conclusions We have developed and validated an innovative clinical prediction model specifically designed to assess the risk of recurrence in residual thyroid tissue. This model serves as a valuable tool for clinicians, facilitating personalized decision-making and representing a significant advancement in the postoperative management of papillary thyroid carcinoma.

Read PDF

Similar papers

Open access Oct 2026

Comparative Performance of the 2015 and 2025 American Thyroid Association Initial Recurrence Risk Stratification Systems in Differentiated Thyroid Cancer.

BACKGROUND The 2025 American Thyroid Association (ATA) guidelines introduced significant modifications to the initial risk stratification system for differentiated thyroid cancer (DTC). However, the real-world prognostic performance and stage migration effects of these updates compared with the 2015 system remain uneva...

Wei-Xun Ke, Xuan-Ling Zheng, Li-Ying Wang et al. · 0 citations
2026

Differentiated Thyroid Cancer Recurrence and Mortality Prognostic Factors: A Retrospective Cohort Study on 350 Adult Patients

The risk of recurrence and death was significantly higher in older age, men, smokers, tumors larger than 4 cm and regional lymph node and regional lymph node, and for each additional year of life the risk of recurrence and death increased by 4% and 9%, respectively.

Hosein Rabiei, Amin Doosti-Irani, Shiva Borzouei · 0 citations
Open access Sep 2026

Clinicopathological and preoperative biomarkers associated with recurrence after primary surgical treatment for endometrial cancer

Background Postoperative recurrence remains a major concern in endometrial cancer (EC), and routinely available preoperative biomarkers may complement established clinicopathological factors. This study aimed to evaluate the associations of preoperative neutrophil-to-lymphocyte ratio (NLR), fibrinogen (FIB), and serum...

Yi-Hua Liu, Bing Wei · 0 citations
Open access Oct 2026

Recurrence patterns and survival outcomes in advanced papillary thyroid carcinoma: a retrospective cohort analysis.

Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor, with a small proportion of patients presenting with advanced disease. The recent European Society of Endocrine Surgeons (ESES) consensus introduced a refined definition of advanced thyroid cancer. This study aimed to characterize real-world c...

A. Lederer, A. Fiedler, J. Staubitz-Vernazza et al. · 0 citations
Open access Aug 2026

Predictive Factors of Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer: A Retrospective Study of 525 Patients

Tumor-related factors remain key predictors of NMIBC outcomes, whereas treatment adherence and socioeconomic factors significantly influence recurrence, highlighting the need for an integrated prognostic model.

R. Es-saady, S. Lafdali, Adnane Mortaji et al. · 0 citations
Open access Oct 2026

Construction and validation of a nomogram based on inflammatory, nutritional and metabolic indicators for predicting the risk of papillary thyroid carcinoma

To analyze the correlation between inflammation, nutrition and metabolic indicators and the risk of papillary thyroid carcinoma (PTC), and to construct and validate a nomogram for predicting PTC risk among patients with thyroid nodules undergoing surgery, to assist clinicians in making more individualized clinical...

Zi-Yu Chen, Hang Su, Hong-Feng Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.